Churchill Pharmaceuticals is focused on bringing value to cancer care by developing quality orally delivered oncology products with clinical profiles addressing efficacy, safety and efficiency. Our commitment to responsibly deliver these products to the patients, payers and healthcare communities we serve is at the core of our business.
Churchill is committed to conducting business ethically and in compliance with the laws and regulations that govern our business and industry. Our Code of Conduct guides our actions, helps us to make the right decisions and provides a framework for our daily interactions with each other as well as our business partners. Every employee is individually responsible for acting in accordance with our Code of Conduct.Follow this link to see our Code of Conduct.
Our commitment to creating value for our partners and responsibly delivering medicines for patients and providers drives our innovation. At Churchill Pharmaceuticals we believe that providing quality products responsibly and enhancing patient access to critical therapies results in true value. With prostate cancer being one of the most prevalent cancers in the United States1 and the cost to patients, systems and payers proving significant,2 Churchill Pharmaceuticals is working to have a meaningful impact on enhancing the value of care for mCRPC patients.
We are proud that we have remained true to our core business values since our company’s formation. These values have endured because we remain fully private and independent. We are backed by Phoenix IP Ventures, a fully integrated Private Equity and Venture Capital Fund that specializes in the Life Sciences, principally in the pharmaceutical sector.
At Churchill, we think differently. The “participant leadership” that defines our culture removes the constraints of “this is how things have to be done” or “this is who has to do it.” We challenge ourselves and each other to be smarter, faster and innovative.